Skip to main content
. 2022 Mar 7;14(5):1354. doi: 10.3390/cancers14051354

Figure 2.

Figure 2

Overall survival following initial treatment. i.p.-PTX, intraperitoneal paclitaxel; Ctrl, control; BSC, best supportive care. The p-value was calculated by log-rank test. The median survival time was 17.9 months in the i.p.-PTX group (n = 43), 10.2 months in the Ctrl group (n = 49), and 1.9 months in the BSC group (n = 9).